On August 4, 2026, a trial status update was recorded for tirzepatide in the GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial.
The trial, registered as NCT06162715, is a Phase 2/3 study. Its current status is listed as active, not recruiting, meaning enrollment has closed but the trial continues.
The GRABS trial is examining GLP-1 receptor agonists, including tirzepatide, in a post-bariatric surgery setting. No results have been posted as part of this update, and no efficacy or safety outcomes are described in the available data.
Tirzepatide is an approved compound, and this trial represents ongoing research into its use in a specific clinical context following bariatric surgery. Status changes like this reflect trial progress rather than findings.
Further updates may be issued as the trial progresses toward completion or as results become available on the registry. For additional background on tirzepatide, readers can consult the compound overview.